GENERAL
Aurobindo Pharma Acquires A1 Biochem Research Unit For ₹147 Cr
Aurobindo Pharma Ltd, through its wholly owned subsidiary Apitoria Pharma Pvt Ltd, has acquired the contract research services business of A1 Biochem Group for ₹147 crore, strengthening its presence across the active pharmaceutical ingredient (API) lifecycle. As part of the transaction, Apitoria now holds an 80% stake in A1 Biochem Labs (India) Pvt Ltd, while […]
CW Bureau
·
Oct 2, 2026
MANUFACTURING
Neogen Chemicals Raises ₹600 Cr Through QIP At A Premium From QIBs
Neogen Chemicals Ltd has raised ₹600 crore through a qualified institutional placement (QIP), issuing 26.61 lakh equity shares to eligible qualified institutional buyers (QIBs). The shares were allotted at ₹2,255 each, including a premium of ₹2,245 per share. The issue price was higher than the floor price of ₹2,189.73. Paid-up capital rises to ₹30 crore […]
CW Bureau
·
Sep 17, 2026
GENERAL
Morepen Completes 1st Phase of API, CDMO Expansion Ahead Of Schedule
Morepen Laboratories has completed the first phase of its manufacturing capacity expansion programme ahead of schedule, increasing its installed reactor capacity for active pharmaceutical ingredients (API) and contract development and manufacturing organisation (CDMO) operations from 535 KL to 614 KL. The capacity addition is expected to strengthen Morepen Laboratories’ manufacturing readiness as the company scales […]
CW Bureau
·
Sep 7, 2026
GENERAL
Piramal Pharma Acquires Additional 40.67% Stake In Yapan Bio For ₹76 Cr
Piramal Pharma Ltd has completed the acquisition of an additional 40.67% stake in Yapan Bio Pvt Ltd for ₹76 crore, taking its total holding in the Hyderabad-based company to 74%. With the completion of the transaction on August 18, Yapan Bio has become a subsidiary of Piramal Pharma. The company is a contract development and […]
CW Bureau
·
Aug 19, 2026
GENERAL
Gland Pharma Signs MSA With Global Pharma Major For Sterile Injectables
Gland Pharma Ltd has entered into a strategic manufacturing and supply agreement (MSA) with a leading global pharmaceutical company for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for international markets. The agreement strengthens Gland Pharma’s position as an integrated end-to-end contract development and manufacturing organisation (CDMO), covering multiple products […]
CW Bureau
·
Aug 9, 2026
GENERAL
Morepen Lab Kicks Off Commercial Execution Of ₹825-Cr CDMO Order
Morepen Laboratories has completed its first commercial dispatch worth ₹50 crore under its ₹825- crore CDMO mandate and expects supplies of around ₹225 crore in Q2 FY2026-27 as it expands manufacturing capacity. Morepen Laboratories Ltd has commenced commercial execution of its recently announced ₹825 crore Contract Development and Manufacturing Organisation (CDMO) mandate by completing its […]
CW Bureau
·
Jul 1, 2026
